EMA warns HQ move may cause major turmoil, seriously delaying new drug approvals
The European Medicines Agency on Tuesday warned that it could lose a majority of its staff based on which of the 19 cities vying to host the medicines regulator is selected by the European Council in November, threatening the pace of new drug approvals even in best-case scenarios for at least two years.
Based on the results of a survey completed by 92% of EMA’s staff earlier this month, the agency says it could lose between 19% and 94% of its staff depending on which city is selected as its future host. Politico first reported that Amsterdam is the top choice among EMA staff.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.